Date. 10/11/2023
LBA34 – Trastuzumab deruxtecan (T-DXd) for pretreated patients with HER2-expressing solid tumors.
Professor Funda Meric-Bernstam presented pivotal findings at the ESMO Congress 2023, shedding light on the latest developments in the realm of cancer treatment. The focal point of her presentation was the noteworthy LBA34 – Trastuzumab deruxtecan (T-DXd) for HER2-expressing solid tumors. These insights emanated from the primary analysis of the DESTINY-PanTumor02 (DP-02) study, offering a comprehensive examination of T-DXd’s efficacy in a diverse cohort of patients.
The study, designed to address the therapeutic potential of T-DXd, specifically targeted patients with HER2 expression who had undergone prior treatment. Professor Meric-Bernstam’s discourse encompassed the enrollment of patients expressing HER2 at levels of 2+ or 3+, spanning seven distinct cohorts representing various disease types. A pan-tumor cohort was also included in this comprehensive investigation.
Key Parameters:
Key parameters under scrutiny included the objective response rate, duration of response, progression-free survival, and overall survival. The results unveiled a notable 37% objective response rate across all cohorts, with particular emphasis on elevated response rates among gynecological patients and those with HER2 expression at 3+. Durable responses were a hallmark of T-DXd, demonstrated by a median response duration of 11 months in the overall cohort and an impressive 22 months in the HER2 3+ subgroup.
In addition to the efficacy findings, Professor Meric-Bernstam discussed safety outcomes, which were in line with expectations for T-DXd. Approximately 40.8% of patients experienced grade 3 or higher adverse events, predominantly drug-related. Despite this, the study highlighted the potential of T-DXd in the landscape of HER2-expressing tumor types, suggesting a tumor-agnostic application.
The results unveiled at the ESMO Congress 2023 underscored the promising role of T-DXd in providing meaningful clinical benefits for patients with pretreated HER2-expressing solid tumors. Professor Funda Meric-Bernstam’s comprehensive overview offered a significant contribution to advancing our understanding of T-DXd’s potential impact on cancer treatment paradigms.